Concurrent administration of atypical antipsychotics and donepezil: Drug interaction study in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 3, 2012, Pages 155-161

  Nirogi, Ramakrishna ^a   Bhyrapuneni, Gopinadh ^a,b   Kandikere, Vishwottam ^a   Benade, Vijay ^a   Muddana, Nageswararao ^a   Saralaya, Ramanatha ^a   Irappanavar, Shantaveer ^a   Ponnamaneni, Ranjithkumar ^a   Mukkanti, K ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Antipsychotics; Coadministration; Donepezil; Drug interaction Pharmacokinetics; Microdialysis

Indexed keywords

ACETYLCHOLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DONEPEZIL; OLANZAPINE; QUETIAPINE;

ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; EXTRACELLULAR SPACE; HALF LIFE TIME; HIPPOCAMPUS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICRODIALYSIS; NONHUMAN; PLASMA CLEARANCE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VENTRAL HIPPOCAMPUS;

EID: 84871267475     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-012-0081-1     Document Type: Article

References (30)

1. Arai M (2000) Parkinsonism onset in a patient concurrently using tiapride and donepezil. Intern Med 39(10):863
2. Barner EL, Gray SL (1998) Donepezil use in Alzheimer disease. Ann Pharmacother 32(1):70-77
3. Bauman W, Pinner G (2002) Use of atypical antipsychotic drugs in old age psychiatry. Adv Psychiatr Treat 8:49-58
4. Becker RE (1994) Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhauser, Boston, pp 1-30
5. Bentué-Ferrer D, Tribut O, Polard E, Allain H (2003) Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17(13):947-963
6. Carcenac D, Martin-Hunyadi C, Kiesmann M, Demuynck-Roegel C, Alt M, Kuntzmann F (2000) Extra-pyramidal syndrome induced by donepezil. Presse Med 29(18):992-993
7. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S et al (1999) A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms in dementia. Neurology 53(5):946-955
8. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (2000) Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Therap 293(1):8-14
9. Edell WS, Tunis SL (2001) Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry 9(3):289-297
10. Giacobini E (1993) Pharmacotherapy of Alzheimer's disease: new drugs and novel strategies. Prog Brain Res 98:447-454
11. Gill SS, Broskill SE, Normand ST, Anderson GM, Sykora K, Lam K et al (2007) Antipsychotics drug use and mortality in older adults with dementia. Ann Intern Med 146(11):775-786
12. Graylands Hospital Drug Bulletin (2006) 14 (1). http://www.watag.org.au/ wapdc/docs/GDB%2014-2%20July06.pdf. Accessed 30 Nov 2011
13. Grutzendler J, Morris C (2001) Cholinesterase inhibitors for Alzheimer's disease. Drugs 61(1):41-52
14. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical ACh release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26(3):325-339
15. Katner S, Bymaster F, Davis R, Nomikos G, Kennedy J, Perry K (2006) The combination of olanzapine and donepezil increases extracellular concentrations of dopamine and acetylcholine in rat prefrontal cortex. In: Proceedings of the 11th international conference on in vivo methods, pp 475-477
16. Liu HC, Lin SK, Sung SM (2002) Extrapyramidal side effects due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci 56(4):479
17. Madhusoodanan S, Brenner R, Cohen CI (1999) Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 12(2):135-150
18. Magnuson TM, Keller BK, Burke WJ (1998) Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry 155(10):1458-1459
19. Parsa MA, Poggi E, Barte L (2000) Treatment of dementia in patients with psychotic and behavioral symptoms with quetiapine and donepezil. J Eur Coll Neuropsychopharmacol 10(3):302
20. Paxinos G, Watson C (2004) Rat brain in stereotaxic coordinates. Academic Press, New York
21. Piraa L, Mongeaua R, Pania L (2004) The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 504(1-2):61-64
22. Reynolds CPL, Strayer SM (1999) Neuroleptics for behavioral symptoms of dementia. J Fam Pract 49(1):78-79
23. Scordo MG, Villa LM, Miglio G, Lombardi G, Dahl ML (2007) Impact of CYP3A4 polymorphism on donepezil plasma levels and therapeutic outcome. Eur Neuropsychopharmacol 17(4): S531-S532
24. Seltzer B (2007) Donepezil: an update. Expert Opin Pharmacother 8(7):1011-1023
25. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26(5):583-594
26. Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F (2005) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518(2-3):140-144
27. Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 46(S1):25-29
28. US Food and Drug Administration (2005) FDA public health advisory - deaths with antipsychotics in elderly patients with behavioural disturbances. FDA/center for drug evaluation and research. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisors/UCMOS3171. htm. Accessed 30 Nov 2011
29. US Food and Drug Administration (2008) Information for healthcare professionals: conventional antipsychotics. FDA/center for drug evaluation and research. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM 124830.htm. Accessed 30 Nov 2011
30. Whitehouse PJ, Price DL, Clarke AW, Coyle JT, DeLong MR (1998) Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10(2):122-126